You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》美银美林升中生制药(01177.HK)目标价至12元 评级「买入」
阿思达克 09-17 10:16

美银美林发表报告指,基於今年上半年业绩表现,更新了对中生制药(01177.HK)的估算模型,进一步调整了对集团仿制药产品线的销售预测及模型参数,并因而调整对集团股份目标价,由10.6元升至12元,重申「买入」评级。

该行称,由於中生制药较高的非控股权益盈利占比,及增长率在2021年後提升,该行的模型估算下调对集团今年至2021年的每股盈利预测,分别降至每股0.24元、0.3元及0.35元人民币。

该行表示,对中生制药的仿制药产品线进行了数次调整,例如将硼替佐米(Bortezomib)、那度胺(Lenalidomide)等药品的销售作独立预测,并加入了18款新公布的仿制药候选药物。总括而言,该行在今年至2021年的仿制药销售预测中包含的药品数量分别为20、19及28款,预测在三年的总销售分别约14亿、43亿及69亿元人民币,可支持集团的收入有稳固增长,及继续在研发上作投资。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account